RU2017137262A3 - - Google Patents

Download PDF

Info

Publication number
RU2017137262A3
RU2017137262A3 RU2017137262A RU2017137262A RU2017137262A3 RU 2017137262 A3 RU2017137262 A3 RU 2017137262A3 RU 2017137262 A RU2017137262 A RU 2017137262A RU 2017137262 A RU2017137262 A RU 2017137262A RU 2017137262 A3 RU2017137262 A3 RU 2017137262A3
Authority
RU
Russia
Application number
RU2017137262A
Other languages
Russian (ru)
Other versions
RU2017137262A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2017137262A publication Critical patent/RU2017137262A/ru
Publication of RU2017137262A3 publication Critical patent/RU2017137262A3/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
RU2017137262A 2015-04-21 2016-04-20 Применение (4-гидрокси-2-метил-1,1-диоксид-2н-бензо[е][1,2]тиазин-3-ил)(нафталин-2-ил)метанона для профилактики и/или лечения неалкогольного стеатогепатита RU2017137262A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1553574A FR3035326B1 (fr) 2015-04-21 2015-04-21 Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphtalen-2-yl)methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique
FR1553574 2015-04-21
PCT/EP2016/058760 WO2016169983A1 (fr) 2015-04-21 2016-04-20 Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphthalen-2-yl) methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique

Publications (2)

Publication Number Publication Date
RU2017137262A RU2017137262A (ru) 2019-05-21
RU2017137262A3 true RU2017137262A3 (cg-RX-API-DMAC7.html) 2019-09-30

Family

ID=53484018

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017137262A RU2017137262A (ru) 2015-04-21 2016-04-20 Применение (4-гидрокси-2-метил-1,1-диоксид-2н-бензо[е][1,2]тиазин-3-ил)(нафталин-2-ил)метанона для профилактики и/или лечения неалкогольного стеатогепатита

Country Status (12)

Country Link
US (1) US20180140609A1 (cg-RX-API-DMAC7.html)
EP (1) EP3285774B1 (cg-RX-API-DMAC7.html)
JP (1) JP2018513175A (cg-RX-API-DMAC7.html)
KR (1) KR20170139030A (cg-RX-API-DMAC7.html)
CN (1) CN107530355A (cg-RX-API-DMAC7.html)
AU (1) AU2016251601A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017021586A2 (cg-RX-API-DMAC7.html)
CA (1) CA2981933A1 (cg-RX-API-DMAC7.html)
FR (1) FR3035326B1 (cg-RX-API-DMAC7.html)
MX (1) MX2017013453A (cg-RX-API-DMAC7.html)
RU (1) RU2017137262A (cg-RX-API-DMAC7.html)
WO (1) WO2016169983A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102177304B1 (ko) * 2018-07-23 2020-11-10 제이투에이치바이오텍 (주) 비알콜성 지방간염의 예방 또는 치료용 약학 조성물
RU2706026C1 (ru) * 2018-12-28 2019-11-13 Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр им. А.С. Логинова Департамента здравоохранения города Москвы Способ лечения неалкогольной жировой болезни печени и сахарного диабета второго типа

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0107383D0 (en) * 2001-03-23 2001-05-16 Univ Edinburgh Lipid profile modulation
JP2007197369A (ja) * 2006-01-26 2007-08-09 Sankyo Co Ltd ベンゾチアジン誘導体
FR2942797B1 (fr) * 2009-03-03 2011-04-29 Pf Medicament Derives de benzothiazines, leur preparation et leur application a titre de medicaments
KR101134447B1 (ko) * 2009-11-30 2012-04-10 에스케이 주식회사 아세트아마이드기를 갖는 사이클릭설폰아미드 유도체, 이의 제조방법 및 이를 함유하는 약학 조성물
JP2011213685A (ja) * 2010-04-01 2011-10-27 Kowa Co ベンゾイミダゾリルピペリジン誘導体を有効成分とする11β−ヒドロキシステロイドデヒドロゲナーゼ1阻害剤
BR112012027640B1 (pt) * 2010-04-29 2021-08-03 The University Of Edinburgh Composto, composição farmacêutica, e, métodos de preparar uma composição farmacêutica, de inibir a função da 11beta-hidroxiesteroide desidrogenase do tipo 1
WO2012144478A1 (ja) * 2011-04-19 2012-10-26 第一三共株式会社 テトラヒドロチアゼピン誘導体

Also Published As

Publication number Publication date
JP2018513175A (ja) 2018-05-24
WO2016169983A1 (fr) 2016-10-27
FR3035326B1 (fr) 2017-05-12
KR20170139030A (ko) 2017-12-18
RU2017137262A (ru) 2019-05-21
MX2017013453A (es) 2017-12-07
BR112017021586A2 (pt) 2018-07-03
EP3285774B1 (fr) 2020-01-08
CA2981933A1 (fr) 2016-10-27
EP3285774A1 (fr) 2018-02-28
FR3035326A1 (fr) 2016-10-28
AU2016251601A1 (en) 2017-11-30
US20180140609A1 (en) 2018-05-24
CN107530355A (zh) 2018-01-02

Similar Documents

Publication Publication Date Title
BR112018002569A2 (cg-RX-API-DMAC7.html)
BR112018004888A2 (cg-RX-API-DMAC7.html)
RU2017137262A3 (cg-RX-API-DMAC7.html)
BE2015C047I2 (cg-RX-API-DMAC7.html)
BR0006866B1 (cg-RX-API-DMAC7.html)
BR0000126B1 (cg-RX-API-DMAC7.html)
BR0000695B1 (cg-RX-API-DMAC7.html)
BR0000763F1 (cg-RX-API-DMAC7.html)
BR0001536B1 (cg-RX-API-DMAC7.html)
BR0001684B1 (cg-RX-API-DMAC7.html)
BR0001810B1 (cg-RX-API-DMAC7.html)
BR0002033B1 (cg-RX-API-DMAC7.html)
BR0002402B1 (cg-RX-API-DMAC7.html)
BR0002435B1 (cg-RX-API-DMAC7.html)
BR0002694B1 (cg-RX-API-DMAC7.html)
BR0002802B1 (cg-RX-API-DMAC7.html)
BR0002874B1 (cg-RX-API-DMAC7.html)
BR0003166B1 (cg-RX-API-DMAC7.html)
BR0003189B1 (cg-RX-API-DMAC7.html)
BR0003208B1 (cg-RX-API-DMAC7.html)
BR0003401B1 (cg-RX-API-DMAC7.html)
BR0003686B1 (cg-RX-API-DMAC7.html)
BR0003746B1 (cg-RX-API-DMAC7.html)
BR0003751B1 (cg-RX-API-DMAC7.html)
BR0003928B1 (cg-RX-API-DMAC7.html)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20200120